Double maintains 2 strategies that include XENE - Xenon Pharmaceuticals, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FMTO | -23.17% | $324.60K | -99.77% | 0.00% |
CBOE | -13.51% | $21.99B | +18.32% | 1.16% |
VSTA | -11.14% | $379.21M | +23.18% | 0.00% |
LITB | -10.56% | $35.12M | -56.39% | 0.00% |
ED | -9.17% | $39.01B | +22.30% | 3.10% |
CME | -8.98% | $93.12B | +21.44% | 4.05% |
CL | -7.94% | $74.46B | +6.74% | 2.17% |
PRPO | -6.51% | $8.12M | -18.77% | 0.00% |
COR | -6.45% | $54.13B | +18.46% | 0.76% |
CHD | -6.10% | $25.54B | +2.16% | 1.11% |
K | -5.94% | $28.36B | +46.23% | 2.76% |
MKTX | -5.85% | $7.93B | -3.43% | 1.41% |
KR | -5.77% | $44.87B | +20.93% | 1.83% |
GIS | -5.76% | $31.31B | -14.67% | 4.17% |
VSA | -5.16% | $3.39M | -81.40% | 0.00% |
CNC | -4.78% | $30.95B | -12.91% | 0.00% |
EXC | -4.52% | $45.55B | +22.61% | 3.41% |
CREG | -3.37% | $5.22M | -57.46% | 0.00% |
VHC | -3.35% | $37.26M | +51.81% | 0.00% |
AWK | -2.80% | $27.92B | +21.50% | 2.13% |
SeekingAlpha
Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data
Yahoo
Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meetingLong-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in focal onset seizures (FOS)Exploratory analysis of efficacy of azetukalner in FOS seizure sub-typesPatient survey findings on mental health and comorbidity burdens of FOS VANCOUVER, British Columbia and BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biophar
Yahoo
VANCOUVER, British Columbia and BOSTON, March 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Stifel 2025 Virtual CNS Forum taking place from March 18-19, 2025. Fireside Chat Presentation Details: Date:Wednesday, March 19, 2025 Time:12:00-12:25 PM Eastern Time Webcast:Reg
Yahoo
XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Yahoo
Xenon Pharmaceuticals Inc (XENE) showcases robust pipeline progress and financial stability, while addressing challenges in clinical trial enrollments and market competition.
SeekingAlpha
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsChad Fugere - Vice President,...
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RCKT | 53.48% | $526.75M | -80.46% | 0.00% |
KYMR | 52.52% | $1.45B | -39.80% | 0.00% |
IDYA | 52.24% | $1.38B | -63.71% | 0.00% |
RVMD | 50.41% | $6.26B | -10.00% | 0.00% |
CRNX | 50.36% | $2.50B | -44.10% | 0.00% |
RGNX | 49.58% | $270.97M | -71.56% | 0.00% |
ATXS | 48.90% | $229.12M | -63.94% | 0.00% |
KN | 48.73% | $1.28B | -9.91% | 0.00% |
ARWR | 47.82% | $1.53B | -56.74% | 0.00% |
IOVA | 47.58% | $1.00B | -76.80% | 0.00% |
DNLI | 47.56% | $1.82B | -34.79% | 0.00% |
OCUL | 47.50% | $1.02B | -22.64% | 0.00% |
CDXS | 47.40% | $186.38M | -27.65% | 0.00% |
GCO | 47.11% | $208.62M | -28.46% | 0.00% |
CTS | 46.86% | $1.11B | -20.72% | 0.43% |
VYGR | 46.79% | $165.07M | -65.95% | 0.00% |
BHVN | 46.55% | $1.75B | -67.98% | 0.00% |
BN | 46.54% | $70.33B | +18.15% | 0.70% |
APGE | 45.98% | $1.78B | -48.41% | 0.00% |
IONS | 45.91% | $4.25B | -37.15% | 0.00% |
Current Value
$30.701 Year Return
Current Value
$30.701 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
VZ | -0.01% | $181.12B | +6.87% | 6.16% |
BTCT | -0.07% | $17.09M | +13.33% | 0.00% |
HRTG | 0.19% | $493.71M | +61.14% | 0.00% |
CI | 0.20% | $88.73B | -7.31% | 1.76% |
KMB | 0.40% | $45.60B | +9.05% | 3.58% |
HIHO | 0.44% | $6.39M | -32.46% | 8.26% |
PM | -0.45% | $235.05B | +69.04% | 3.53% |
WEC | 0.47% | $33.32B | +32.90% | 3.23% |
OXBR | 0.54% | $10.87M | +41.75% | 0.00% |
HRB | -0.62% | $7.64B | +21.63% | 2.55% |
PRT | -0.63% | $43.92M | -13.84% | 12.40% |
T | 0.73% | $189.43B | +60.72% | 4.18% |
CYD | 0.74% | $592.85M | +75.88% | 2.60% |
PEP | 0.79% | $197.66B | -14.39% | 3.75% |
STG | -0.82% | $24.92M | -45.94% | 0.00% |
HSY | 0.88% | $33.24B | -13.41% | 3.33% |
MNOV | 0.92% | $62.29M | -18.59% | 0.00% |
GO | -0.96% | $1.38B | -47.83% | 0.00% |
LTM | 0.97% | $8.36B | -100.00% | <0.01% |
SO | 1.17% | $97.49B | +27.75% | 3.23% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBTO | 0.03% | $331.32M | 0.07% |
CMBS | -0.04% | $425.19M | 0.25% |
TYA | 0.04% | $144.02M | 0.15% |
GOVT | -0.08% | $26.81B | 0.05% |
IBTK | 0.08% | $413.82M | 0.07% |
GOVZ | -0.15% | $257.94M | 0.1% |
FLGV | -0.22% | $953.70M | 0.09% |
KRBN | -0.27% | $146.09M | 0.85% |
IBTJ | -0.28% | $641.75M | 0.07% |
IEF | -0.28% | $37.74B | 0.15% |
CANE | -0.29% | $10.45M | 0.29% |
SPTI | 0.44% | $9.65B | 0.03% |
NYF | 0.59% | $835.71M | 0.25% |
SCHR | -0.59% | $10.43B | 0.03% |
BSSX | 0.61% | $72.99M | 0.18% |
IBTG | -0.70% | $1.84B | 0.07% |
SUB | 0.76% | $8.64B | 0.07% |
LMBS | -0.76% | $4.87B | 0.64% |
FLDR | -0.77% | $768.43M | 0.15% |
IBTM | -0.77% | $314.60M | 0.07% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -42.71% | $403.24M | 1.43% |
TAIL | -37.54% | $101.24M | 0.59% |
VIXY | -35.73% | $195.31M | 0.85% |
SHYM | -22.42% | $301.08M | 0.35% |
IVOL | -20.05% | $492.66M | 1.02% |
FTSD | -17.13% | $219.44M | 0.25% |
USDU | -14.93% | $216.58M | 0.5% |
UUP | -10.86% | $258.38M | 0.77% |
STPZ | -10.03% | $448.72M | 0.2% |
XONE | -9.67% | $626.27M | 0.03% |
BILZ | -8.76% | $791.45M | 0.14% |
DFNM | -7.59% | $1.51B | 0.17% |
TPMN | -7.47% | $30.62M | 0.65% |
EQLS | -7.07% | $4.92M | 1% |
AGZ | -6.86% | $636.07M | 0.2% |
CTA | -6.85% | $1.00B | 0.76% |
SMB | -5.76% | $262.32M | 0.07% |
SPTS | -5.57% | $6.21B | 0.03% |
CGSM | -5.50% | $636.60M | 0.25% |
FMHI | -5.46% | $723.33M | 0.7% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 65.40% | $4.92B | 0.35% |
IBB | 62.03% | $5.33B | 0.45% |
GNOM | 58.45% | $46.24M | 0.5% |
XPH | 58.31% | $143.33M | 0.35% |
IWC | 57.59% | $747.43M | 0.6% |
FBT | 57.57% | $1.02B | 0.56% |
PBE | 56.72% | $215.97M | 0.58% |
IWO | 55.96% | $10.46B | 0.24% |
PINK | 54.82% | $135.31M | 0.5% |
VTWO | 54.77% | $10.64B | 0.07% |
KOMP | 54.70% | $1.94B | 0.2% |
IWM | 54.34% | $60.51B | 0.19% |
KJAN | 54.13% | $300.51M | 0.79% |
KAPR | 54.03% | $167.86M | 0.79% |
ARKG | 53.95% | $959.87M | 0.75% |
VBK | 53.75% | $16.64B | 0.07% |
SCHA | 53.72% | $15.29B | 0.04% |
ISCG | 53.55% | $627.41M | 0.06% |
PTH | 53.30% | $101.34M | 0.6% |
BBH | 53.23% | $342.00M | 0.35% |